刘赟,马骏,卜东魁,李红,陈明

• 1:青岛思达心脏医院心内科

摘要(Abstract)：

<正>1前言心力衰竭是一种由于心脏结构或功能异常导致的心室充盈或射血功能损失的复杂综合征,其临床表现为呼吸困难、脚踝肿胀和疲劳,伴随着由心脏结构以及功能异常导致的颈静脉压力升高、肺充血和周围水肿[1]。世界范围内有1%~2%的人群患有心力衰竭,随着人口老龄化和对急性心肌梗死、高脂血症、高血压病二级预防水平的提高,心力衰竭的发病率和医疗耗资日益增加[2-3]。正确认识和评估心力衰竭的类型、发病机制和发展进程是治疗的基础。《中国心力衰竭诊断和治疗指南(2014)》[4]按

关键词(KeyWords)： 心力衰竭;药物治疗;非药物治疗;中医药

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 刘赟,马骏,卜东魁,李红,陈明

参考文献(References)：

• [1]Ponikowski P,Voors AA.,Anker SD.,et al.2016 Esc Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure:The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology(Esc).Developed with the Special Contribution of the Heart Failure Association(Hfa)of the Esc.Eur J Heart Fail,2016,18(8):891-975.
• [2]Metra M,Carubelli V,Ravera A,et al.Heart Failure 2016:S till More Questions Than Answers.Int J Cardiol,2017,227:766-777.
• [3]赵凯,李永健.药物治疗心力衰竭新进展.重庆医学,2014,43(3):371-378.
• [4]中华医学会心血管病学分会.中国心力衰竭诊断和治疗指南(2014).中华心血管病杂志,2014,42(2):3-10.
• [5]Ponikowski P,Voors AA.,Anker SD,et al.2016 ESC Gui delines for the Diagnosis and Treatment of Acute and Chronic Heart Failure.Rev Esp Cardiol(Engl Ed),2016,69(12):1167
• [6]袁祖贻,刘治全.心力衰竭治疗的战略转移——心力衰竭学说的思维变迁与未来治疗展望.医学与哲学,1995,16(9):472-473.
• [7]胡大一.慢性充血性心力衰竭药物治疗的现代观点与最新进展.中国实用内科杂志,2000,20(1):6-8.
• [8]Yancy CW,Jessup M,Bozkurt B,et al.2013 ACCF/AHA Guid eline for the Management of Heart Failure:a report of the Ameri can College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.J Am Coll Cardiol,2013,62(16):e147-239.
• [9]Heggermont WA,Goethals M,Dierckx R,et al.Should Mras Be at th e Front Row in Heart Failure?A Plea for the Early Use of Mineral ocorticoid Receptor Antagonists in Medical Therapy for Heart Failure Based on Clinical Experience.Heart Fail Rev,2016,21(6):699-701
• [10]Nabeebaccus A,Zheng S,Shah AM.Heart FailurePotential New Targets for therapy.Br Med Bull,2016,119(1):99-110.
• [11]Mc Murray JV,Packer M,Desai AS,et al.Dual Angiotensin Receptor and Neprilysin Inhibition as an Alternative to Angiotensin-Converting Enzyme Inhibition in Patients with Chronic Systolic Heart Failure:Rationale for and Design of the Prospective Comparison of Arni with Acei to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial(Paradigm-Hf).Eur J Heart Fail,2013,15(9):1062-1073.
• [12]Lother A,Hein L.Pharmacology of Heart Failure:From Basic Science to Novel Therapies.Pharmacol Ther,2016,166:136-149.
• [13]Mc Cormack PL.Sacubitril/Valsartan:A Review in Chronic Heart Failure with Reduced Ejection Fraction.Drugs,2016,3:387-396.
• [14]Greenberg B.Novel Therapies for Heart Failure-Where Do They Stand?Circ J,2016,80(9):1882-1891.
• [15]Ghosh RK.,Banerjee K,Tummala R,et al.Serelaxin in Acute Heart Failure:Most Recent Update on Clinical and Preclinical Evidence.Cardiovasc Ther,2017,35(1):55-63.
• [16]Hayes David L,Abraham T.Clinical Trials Supporting Current Indications for CRT.Cardiac Resynchronization Therapy(second Edition),2009,261-276.
• [17]Borganelli Mark,Wolfe Douglas,Mccearley Sandra,et al.Significance of Left Axis Deviation on Crt Response:Analysis of Miracle&Miracle Icd.J Card Fail,2010,8:S96.
• [18]Bristow MR,Saxon LA,Feldman AM,et al.Lessons Learned and Insights Gained Inthedesign,Analysis,and Outcomes Ofthe Companion Trial.JACC Heart Fail,2016,4(7):521-535.
• [19]Moss AJ,Brown MW,Cannom DS,et al.Multicenter A u t o m a t i c D e f i b r i l l a t o r I m p l a n t a t i o n Tr i a l-C a r d i a c Resynchronization Therapy(Madit-Crt):Design and Clinical Protocol.Ann Noninvasive Electrocardiol,2005,10(4 Suppl):34-43.
• [20]Jancin Bruce.Care-Hf:Median Survival Is 7 Years Post-Crt.Internal Medicine News,2010,19:14.
• [21]华伟,樊晓寒.慢性心力衰竭治疗的新选择——器械治疗.中国循环杂志,2016,(31)6:529-531.
• [22]Rinaldi CA,Leclercq C,Kranig W,et al.Improvement in Acute Contractility and Hemodynamics with Multipoint Pacing Via a Left Ventricular Quadripolar Pacing Lead.J Interv Card Electrophysiol,2014,40(1):75-80.
• [23]Rinaldi CA,Burri H,Thibault B,et al.A Review of Multisite Pacing to Achieve Cardiac Resynchronization Therapy,Europace,2015,17(1):7-17.
• [24]Daubert JC,Saxon L,Adamson PB,et al.2012 EHRA/HRS Expert Consensus Statement on Cardiac Resynchronization T h e r a p y i n H e a r t Fa i l u r e:I m p l a n t a n d Fo l l o w-u p Recommendations and Management.Heart Rhythm,2012,9(9):1524-1576.
• [25]Forleo Giovanni B,Santini Luca,Giammaria Massimo,et al.Multipoint Pacing Via a Quadripolar Left-Ventricular Lead:Preliminary Results from the Italian Registry on Multipoint LeftVentricular Pacing in Cardiac Resynchronization Therapy(IRONMPP).Europace,2017,19(7):1170-1177.
• [26]Reddy Vivek Y,Miller Marc A,Neuzil Petr,et al.Cardiac Resynchronization Therapy with Wireless Lef t Ventricular Endocardial Pacing:The SELECT-LV Study.J Am Coll Cardiol,2017,69(17):2119-2129
• [27]Reddy Vivek Y,Neuzil Petr,Riahi Sam,et al.109-03:Leadless Lv Endocardial Stimulation for Crt:Final Outcomes of SelectLv Study,EP Europace,2016,suppl_1:i85-i85.
• [28]Behar JM,Sieniewicz B,Mountney P,et al.Image Integration to Guide Wireless Endocardial Lv Electrode Implantation for Crt.JACC Cardiovasc Imaging,2017,10(12):1526-1528..
• [29]左嵩,刘念,董建增,等.以钙调控蛋白为靶点的心力衰竭基因治疗.中华心血管病杂志,2016,44(6):470-473.
• [30]Greenberg B,Yaroshinsky A,Zsebo KM,et al.Design of a Phase 2b Trial of Intracoronary Administration of Aav1/Serca2a in Patients with Advanced Heart Failure:The Cupid 2 Trial(Calcium up-Regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease Phase 2b).JACC Heart Fail,2014,2(1):84-92.
• [31]Hulot Jean‐Sébastien,Salem Joe‐Elie,Redheuil Alban,et al.Effect of Intracoronary Administration of Aav1/Serca2a on Ventricular Remodelling in Patients with Advanced Systolic Heart Failure:Results from the Agent‐Hf Randomized Phase 2Trial.Eur J Heart Fail,2017,19(11):1534-1541.
• [32]Garbade J,Barten MJ,Bittner HB,et al.Heart Transplantation and Left Ventricular Assist Device Therapy:Two Comparable Options in End‐Stage Heart Failure?Clin Cardiol,2013,36(7):378-382.
• [33]Lund Lars H,Edwards Leah B,Dipchand Anne I,et al.The Registry of the International Society for Heart and Lung Transplantation:Thirty-Third Adult Heart Transplantation Report—2016;Focus Theme:Primary Diagnostic Indications for Transplant,J Heart Lung Transplant,2016,35(10):1170-1184.
• [34]Youn JC.,Han S,Ryu KH.Temporal Trends of Hospitalized Patients with Heart Failure in Korea.Korean Circ J,2017,47(1):16-24.
• [35]余文静,高兴莲,王曾妍,等.146例脑死亡器官捐献心脏移植手术期管理.临床心血管病杂志,2016(4):418-421.
• [36]陈燕.北京地区慢性心力衰竭患者延续性照护模式的初步探索.北京:北京协和医学院,2013.
• [37]薛礼.心力衰竭患者强化管理干预与常规管理干预治疗的临床疗效对比研究,石河子:石河子大学,2013.
• [38]金杨杨.家庭随访改善慢性心力衰竭患者症状困扰的研究.护士进修杂志,2013,28(10):930-932.
• [39]赵海松,杨震,冯玲,等.慢性心力衰竭疾病管理对患者预后的影响.实用糖尿病杂志,2013(2):42-45.
• [40]Bernocchi P,Scalvini S,Galli T,et al.A Multidisciplinary T elehealth Program in Patients with Combined Chronic Obstruct ive Pulmonary Disease and Chronic Heart Failure:Study Prot ocol for a Randomized Controlled Trial.Trials,2016,17(1):462.
• [41]Díez I,Garcia-Zapirain B,Méndez-Zorrilla A,et al.Monitoring and Follow-up of Chronic Heart Failure:A Literature Review of Ehealth Applications and Systems.J Med Syst,2016,40(7):179.
• [42]Creber RM,Maurer MS,Reading M,et al.Review and Analysis of Existing Mobile Phone Apps to Support Heart Failure Symptom Monitoring and Self-Care Management Using the Mobile Application Rating Scale(Mars).JMIR Mhealth Uhealth,2016,40(7):1-9.
• [43]Bashi N,Karunanithi M,Fatehi F,et al.Remote Monitoring of Patients with Heart Failure:An Overview of Systematic Reviews.J Med Internet Res,2017,19(1):e18.
• [44]Samuel OW,Asogbon GM,Sangaiah AK,et al.An Integrated Decision Support System Based on Ann and Fuzzy_Ahp for Heart Failure Risk Prediction,Expert Syst Appl,2017,68(2):163-172.
• [45]Mc Ilvennan CK,Allen LA.Palliative Care in Patients with Heart Failure,BMJ,2016,353:113-126
• [46]陈立新,林惠珍,吴业荣.定期监测NT-pro BNP在基层医院慢性心力衰竭治疗中的应用.承德医学院学报,2016,33(3):201-202.
• [47]Shah SJ,Kitzman DW,Borlaug BA,et al.Phenotype-Specific Treatment of Heart Failure with Preserved Ejection Fraction a Multiorgan Roadmap.Circulation,2016,134(1):73-90.
• [48]Paulus WJ,Tschope CA.Novel Paradigm for Heart Failure with Preserved Ejection Fraction Comorbidities Drive Myocardial Dysfunction and Remodeling through Coronary Microvascular Endothelial Inflammation.J Am Coll Cardiol,2013,62(4):263-71.
• [49]Borlaug BA.The Pathophysiology of Heart Failure with Preserved Ejection Fraction,Nat Rev Cardiol,2014,11(9):507-515.
• [50]陈统.地尔硫联合芪苈强心胶囊治疗射血分数保留性心力衰竭的临床疗效分析.延安:延安大学,2014.
• [51]赵颖.舒张性心力衰竭气虚血瘀证超声心动相关指标研究及益气泻肺汤干预的临床观察.北京:北京中医药大学,2013.
• [52]蔡宇.参附汤加味在充血性心力衰竭治疗中的应用体会,中国卫生产业,2011,8(11):5-5.
• [53]辛莉.健心颗粒改善射血分数保留的心力衰竭患者生存质量的临床研究.福州:福建中医药大学,2015.
• [54]饶明月,张国茹,王亚玲,等.干细胞治疗心力衰竭的研究进展.医学综述,2016,2(19):3774-3779.
• [55]刘圣辰,王强,卢子润,等.骨髓间充质干细胞治疗充血性心力衰竭的研究现状.中国胸心血管外科临床杂志,2016,23(11):1108-1111.
• [56]Oh H,Ito H,Sano S.Challenges to Success in Heart Failure:Cardiac Cell Therapies in Patients with Heart Diseases.J Cardiol,2016,68(5):361-367
• [57]Terzic A,Behfar A.Stem Cell Therapy for Heart Failure:Ensuring Regenerative Proficiency.Trends Cardiovasc Med,2016,26(5):395-404.
• [58]龚惠,陈志丹,邹云增.干细胞与心肌再生.上海大学学报(自然科学版),2016,22(3):280-284.